National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-14: The Prospects for Immunizing Against Salmonella typhi." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
327
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

orally or parenterally, and 3 weeks later the vaccinated and control calves were challenged orally with pathogenic S. typhimurium (Robertsson et al., 1983). The oral attenuated vaccine protected significantly better than the parenteral killed vaccine. These results are sufficiently promising to evoke interest in analogous aromatic-dependent S. typhi oral vaccine strains for human use.

New vaccines to protect against typhoid fever, particularly the live oral vaccines, provide an opportunity for the disease control in endemic areas. However, further vaccine studies are impeded by the lack of understanding of the immunological basis of protection and the lack of suitable animal models for typhoid fever. At this point, the only way to assess the efficacy of a vaccine is through large-scale field trials in endemic areas.

REFERENCES

Germanier, R. 1984. Typhoid fever. Pp. 137–165 in Bacterial Vaccines, R.Germanier, ed. New York: Academic Press.

Germanier, R., and E.Furer. 1975. Isolation and characterization of S. typhi gal E mutant Ty21a: A candidate strain for a live oral typhoid vaccine. J. Infect. Dis. 131:553–558.


Hoiseth, S.K., and B.A.D.Stocker. 1981. Aromatic dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291:238.

Hornick, R.B. 1982. Typhoid fever. Pp. 659–676 in Bacterial Infections of Humans, A.S.Evans and H.A.Feldman, eds. New York: Plenum.

Hornick, R.B. 1985. Selective primary health care: strategies for the control of diseases in the developing world. XX. Typhoid fever. Rev. Infect. Dis. 7:536–546.


Levin, D.M., K.H.Wong, H.V.Reynolds, A.Sutton, and R.S.Northrup. 1975. Vi antigen from Salmonella typhosa and immunity against typhoid fever. II. Safety and immunogenicity in humans. Infect. Immun. 12:1290–1294.

Levine, M.M., J.B.Kaper, R.E.Black, and M.L.Clements. 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47:510–550.


National Institute of Allergy and Infectious Diseases. 1985. Program on Accelerated Development of New Vaccines. Progress Report. Bethesda, Md.: National Institutes of Health.


Punjabi, N.H. 1984. Paper presented at the International Workshop on Typhoid Fever, Pan American Health Organization, Washington, D.C., November 29–30, 1984.


Robertsson, J.A., A.A.Lindberg, S.Hoiseth, and B.A.D.Stocker. 1983. Salmonella typhimurium infection in calves: Protection and survival of virulent challenge bacteria after immunization with live or inactivated vaccines. Infect. Immun. 41:742–750.

Page
327
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)